Available IPD datapackage for study 'Phase 1 Randomized, Blinded, Placebo-Controlled Study of Single Ascending Doses of BIIB063 in Healthy Volunteers'

The primary objective of the study is to evaluate the safety and tolerability of single
ascending intravenous (IV) doses and a single subcutaneous (SC) dose of BIIB063 in healthy
volunteers. The secondary objectives of the study are to estimate the PK parameters of single
ascending IV doses of BIIB063; to estimate the PK parameters and absolute bioavailability (F)
of a single SC dose of BIIB063; and to evaluate the immunogenicity of single ascending doses
of BIIB063.